Ciplamed

Mumbai, India Founded: 2001 • Age: 25 yrs Listed
Offers online medical news, guidelines, and educational content for professionals.
Request Access
Report Incorrect Data
Page last updated

About Ciplamed

Ciplamed is a publicly listed company based in Mumbai (India) founded in 2001. It offers online medical news, guidelines, and educational content for professionals. It operates on a B2B model. The company has 25,952 employees. Its Indian entity Cipla Limited reported revenue of ₹39,894 Cr. Ciplamed offers products and services including eCME, Webcasts, and Quick Reads. Its focus areas include Biotechnology, Pharmaceutical Services, Knowledge Platforms and Professional Content.

Company details

CiplaMed, operated by Cipla Limited, delivers digital resources like medical updates, conference highlights, and webcasts. Based in Mumbai, India, it focuses on healthcare education through platforms for eCME, expert talks, and patient materials, serving professionals to enhance knowledge and practice in areas such as cardiovascular and respiratory health.

  • Headquarters Mumbai, India
  • Employees 25,952
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Website ciplamed.com
  • Legal Name Cipla Limited
  • Date of Incorporation 17 Aug, 1935
  • Jurisdiction Mumbai, Maharashtra, India
Operational Areas
Healthcare → Life Sciences Platforms & Tools
Healthcare → Digital Health & Telemedicine
Key Metrics
  • Market Cap
    ₹1,08,093 Cr

    CIPLA · NSE

  • Share Price
    ₹1,355.00

    +1.27% today

  • Revenue
    ₹39,012 Cr

    FY 2025-26 · +5.3% YoY

  • EBITDA
    ₹5,607 Cr

    Margin 14.4%

  • Net Profit
    ₹3,806 Cr

    FY 2025-26 · -26.0% YoY

  • P/E (TTM)
    30.2x

    P/B 3.1x

  • ROE
    11.8%

    ROCE 15.7%

  • Debt / Equity
    0.02

    Interest cover 1.2x

  • Employee Count
    25,952

Products & Services of Ciplamed

Ciplamed offers a comprehensive portfolio of products and services, including eCME, Webcasts, and Quick Reads.

eCME
Education Platform

Online platform for continuing medical education

Webcasts
Media Service

Live and recorded expert discussions on health topics

Quick Reads
Content Service

Summaries of medical news and guidelines

Board of directors of Cipla Limited (Ciplamed)

Cipla Limited is the primary company behind Ciplamed. The board of Cipla Limited currently have 10 directors; the longest-serving is Yusuf Khwaja Hamied, appointed in 1972. 32 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Yusuf Khwaja Hamied
DIN 00029049
Director21 Jul 197254 yrs 3 moCipla Limited
Adil Zainulbhai
DIN 06646490
Director23 Jul 201412 yrs 3 moCipla Limited
Prathivadibhayankara Rajagopalan Ramesh
DIN 01915274
Director01 Jul 20215 yrs 3 moCipla Limited
Mandar Purushottam Vaidya
DIN 09690327
Director29 Jul 20224 yrs 2 moCipla Limited
Balram Bhargava
DIN 10479707
Director01 Apr 20242 yrs 6 moCipla Limited
Sharmila Nitin Paranjpe
DIN 02328770
Director01 Sep 20242 yrs 1 moCipla Limited
Abhijit Jagdish Joshi
DIN 07115673
Director03 Sep 20242 yrs 1 moCipla Limited
Kamil Hamied
DIN 00024292
Director01 Nov 20241 yr 11 moCipla Limited
Maya Hari
DIN 01123969
Director01 Nov 20241 yr 11 moCipla Limited
Achin Gupta
DIN 09491674
Managing Director01 Apr 20266 moCipla Limited

IPO & Listings of Ciplamed

Ciplamed is a publicly listed company on the NSE with ticker symbol CIPLA in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: CIPLA
  • Listed entityCipla Limited
  • Exchange sectorPharmaceuticals

Financials of Ciplamed

Exchange-reported figures of Cipla Limited, the listed company behind Ciplamed (NSE: CIPLA).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹39,012 Cr
+5.3% YoY
EBITDA
₹5,607 Cr
-21.3% YoY
Profit After Tax
₹3,806 Cr
-26.0% YoY
Net Worth
₹34,432 Cr
+10.4% YoY
Total Assets
₹35,561 Cr
+11.0% YoY
Total Debt
₹614 Cr
+40.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue39,01237,03935,41530,93829,71928,22717,132
Revenue growth+5.3%+4.6%+14.5%+4.1%+5.3%+64.8%-
EBITDA5,6077,1286,0964,8454,3714,2523,206
EBITDA margin+14.4%+19.2%+17.2%+15.7%+14.7%+15.1%+18.7%
Profit before tax5,2246,8215,7024,0383,4933,2902,178
Net profit3,8065,1464,2072,8422,5822,3691,458
Net profit margin+9.8%+13.9%+11.9%+9.2%+8.7%+8.4%+8.5%
EPS (₹)48.0265.2951.0534.7131.1929.8219.18
Balance sheet
Total assets35,56132,03527,62124,78522,42520,87819,351
Net worth34,43231,19326,70623,40820,84218,32715,763
Total debt6144385598031,0562,0142,816
Cash & bank1,3078008751,5651,9281,4011,004
Net working capital9,68510,6589,6749,2008,0846,9466,744
Cash flow
Cash from operations3,9405,0054,1343,2383,3263,7553,068
Cash from investing(2,234)(3,682)(2,982)(2,376)(1,858)(2,374)114
Cash from financing(1,234)(1,293)(1,200)(958)(1,600)(1,240)(2,949)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue7,1196,5417,0747,5896,9576,7307,0737,051
Revenue growth (YoY)+2.3%-2.8%+0.0%+7.6%+3.9%---
Other income211148206269259289222191
EBITDA1,1929559791,8951,7781,5381,9891,886
EBITDA margin+16.8%+14.8%+14.1%+25.4%+26.0%+23.3%+28.6%+27.1%
Depreciation304383278297253309280272
Interest17.0313.1314.0313.1814.0514.0214.6415.40
Profit before tax1,0827078931,8541,7701,5041,9161,789
Tax295157219500478279332483
Net profit7875506751,3531,2921,2251,5841,306
EPS (₹)9.766.868.3616.7216.0615.1219.4316.12
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue20,06519,95217,48315,05815,38111,30312,659
Revenue growth+0.6%+14.1%+16.1%-2.1%+36.1%-10.7%-
EBITDA4,1915,7784,4843,1673,7113,0672,707
EBITDA margin+20.9%+29.0%+25.7%+21.0%+24.1%+27.1%+21.4%
Profit before tax4,6366,4695,3103,3753,8803,2082,964
Net profit3,4424,8134,0382,5552,9092,4292,227
Net profit margin+17.2%+24.1%+23.1%+17.0%+18.9%+21.5%+17.6%
EPS (₹)43.5263.8650.5031.1436.6630.6128.75
Balance sheet
Total assets34,66732,41428,17424,87522,71820,19017,679
Net worth34,20132,09927,97424,63822,51419,92817,403
Total debt12511745.5550.0923.4552.126.06
Cash & bank5192783339661,428875523
Net working capital7,3188,3687,6287,9156,6455,5185,579
Cash flow
Cash from operations2,8323,3013,7273,0352,7733,4602,018
Cash from investing(1,344)(2,309)(2,883)(2,758)(2,464)(3,361)(1,127)
Cash from financing(1,322)(1,074)(709)(425)(427)(65.80)(694)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue5,0784,2104,4985,2265,0464,7984,9714,775
Revenue growth (YoY)+0.6%-12.3%-9.5%+9.4%+12.1%---
Other income243180417255271588189289
Total expenses3,9923,6434,0213,7033,4223,4793,3093,337
EBITDA1,0865674771,5231,6241,3191,6621,438
EBITDA margin+23.2%+14.8%+11.2%+33.9%+36.1%+31.0%+40.2%+36.2%
Depreciation169218153141146148143146
Interest5.686.744.032.655.883.493.553.00
Profit before tax1,1545227361,6331,7441,7561,7041,578
Tax291138119423441270266400

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 26 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue7,1196,5417,0747,5896,9576,7307,0737,051
Revenue growth (YoY)+2.3%-2.8%+0.0%+7.6%+3.9%---
Other income211148206269259289222191
EBITDA1,1929559791,8951,7781,5381,9891,886
EBITDA margin+16.8%+14.8%+14.1%+25.4%+26.0%+23.3%+28.6%+27.1%
Depreciation304383278297253309280272
Interest17.0313.1314.0313.1814.0514.0214.6415.40
Profit before tax1,0827078931,8541,7701,5041,9161,789
Tax295157219500478279332483
Net profit7875506751,3531,2921,2251,5841,306
EPS (₹)9.766.868.3616.7216.0615.1219.4316.12
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue39,01237,03935,41530,93829,71928,22717,132
Revenue growth+5.3%+4.6%+14.5%+4.1%+5.3%+64.8%-
Other income882862747475281266344
Total expenses33,40529,91129,31926,09325,34923,97513,926
Employee cost5,3664,8334,3103,8303,5303,2523,027
EBITDA5,6077,1286,0964,8454,3714,2523,206
EBITDA margin+14.4%+19.2%+17.2%+15.7%+14.7%+15.1%+18.7%
Depreciation1,2111,1071,0511,1721,0521,0681,175
Interest54.3962.0189.88110106161197
Profit before tax5,2246,8215,7024,0383,4933,2902,178
Tax1,3541,5301,5471,203934889631
Net profit3,8065,1464,2072,8422,5822,3691,458
Net profit margin+9.8%+13.9%+11.9%+9.2%+8.7%+8.4%+8.5%
EPS (₹)48.0265.2951.0534.7131.1929.8219.18
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital162162161161161161161
Reserves & surplus34,27031,03226,54523,24620,68018,16515,602
Shareholders' funds (net worth)34,43231,19326,70623,40820,84218,32715,763
Minority interest88.2995.8095.90306276259294
Secured loans0.0011.9891.77429376392423
Unsecured loans6144264683746801,6222,393
Total debt6144385598031,0562,0142,816
Total liabilities35,56132,03527,62124,78522,42520,87819,351
Assets
Gross block23,42219,55318,14617,12216,96815,78715,151
Net block12,43410,0069,6079,1609,6839,5169,683
Capital work in progress2,0421,5661,1531,093766969825
Investments8,2237,9335,4493,6622,5512,7101,471
Inventories6,5975,6425,2385,1565,3504,6694,378
Sundry debtors5,6205,5064,7714,0573,4243,4463,891
Cash & bank balances1,3078008751,5651,9281,4011,004
Loans & advances2,9424,0073,7022,9371,8131,4071,417
Total current assets16,46615,95614,58513,71512,51610,92310,690
Total current liabilities6,7825,2984,9124,5154,4323,9773,946
Net working capital9,68510,6589,6749,2008,0846,9466,744
Total assets35,56132,03527,62124,78522,42520,87819,351
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash543512561658790649508
Net cash from operating activities3,9405,0054,1343,2383,3263,7553,068
Net cash from investing activities(2,234)(3,682)(2,982)(2,376)(1,858)(2,374)114
Net cash from financing activities(1,234)(1,293)(1,200)(958)(1,600)(1,240)(2,949)
Net change in cash47330.31(48.99)(96.78)(132)141234
Closing cash1,3078008751,5651,9281,4011,004
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+5.3%+4.6%+14.5%+4.1%+5.3%+64.8%-
EBITDA growth-21.3%+16.9%+25.8%+10.8%+2.8%+32.6%-
PBT growth-23.4%+19.6%+41.2%+15.6%+6.2%+51.1%+4.8%
Net income growth-26.0%+22.3%+48.0%+10.1%+9.0%+62.5%-
Revenue CAGR (3Y)+8.0%+7.6%+7.9%+21.8%+22.0%+23.0%+6.0%
EBITDA CAGR (3Y)+5.0%+17.7%+12.8%+14.8%+12.2%+15.7%+9.0%
Profitability & leverage
Net income margin+9.9%+14.3%+11.7%+9.2%+8.6%+8.5%+9.0%
Return on capital employed+15.7%+23.2%+22.3%+17.8%+16.8%+17.4%+12.2%
Return on net worth+11.8%+18.3%+16.6%+12.8%+13.1%+14.1%+10.1%
Debt / equity0.020.020.030.040.080.140.23
Long-term debt / equity0.010.010.010.020.050.110.20
Interest cover1.241.031.782.983.205.059.72
Efficiency & per share
Fixed asset turnover1.821.962.011.821.811.821.18
Inventory turnover6.386.816.815.895.936.244.11
Debtors turnover7.017.218.028.278.657.694.26
EPS (₹)48.0265.2951.0534.7131.1929.8219.18
Dividend per share (₹)13.0016.0013.008.505.005.004.00
Book value per share (₹)426.24386.25330.79290.01258.33227.25195.51
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue5,0784,2104,4985,2265,0464,7984,9714,775
Revenue growth (YoY)+0.6%-12.3%-9.5%+9.4%+12.1%---
Other income243180417255271588189289
Total expenses3,9923,6434,0213,7033,4223,4793,3093,337
EBITDA1,0865674771,5231,6241,3191,6621,438
EBITDA margin+23.2%+14.8%+11.2%+33.9%+36.1%+31.0%+40.2%+36.2%
Depreciation169218153141146148143146
Interest5.686.744.032.655.883.493.553.00
Profit before tax1,1545227361,6331,7441,7561,7041,578
Tax291138119423441270266400
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue20,06519,95217,48315,05815,38111,30312,659
Revenue growth+0.6%+14.1%+16.1%-2.1%+36.1%-10.7%-
Other income1,1231,2791,434826742654893
Total expenses15,87414,17412,99911,89111,6708,2359,952
Employee cost3,3503,0552,6892,3812,1221,7041,911
EBITDA4,1915,7784,4843,1673,7113,0672,707
EBITDA margin+20.9%+29.0%+25.7%+21.0%+24.1%+27.1%+21.4%
Depreciation658574588596547469600
Interest19.3015.1120.2522.2726.9345.0736.05
Profit before tax4,6366,4695,3103,3753,8803,2082,964
Tax1,1211,3111,233862922739646
Net profit3,4424,8134,0382,5552,9092,4292,227
Net profit margin+17.2%+24.1%+23.1%+17.0%+18.9%+21.5%+17.6%
EPS (₹)43.5263.8650.5031.1436.6630.6128.75
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital162162161161161161161
Reserves & surplus34,04031,93827,81224,47722,35219,76617,242
Shareholders' funds (net worth)34,20132,09927,97424,63822,51419,92817,403
Secured loans0.000.000.000.000.000.000.00
Unsecured loans12511745.5550.0923.4552.126.06
Total debt12511745.5550.0923.4552.126.06
Total liabilities34,66732,41428,17424,87522,71820,19017,679
Assets
Gross block10,5008,6708,0467,7667,3887,0666,698
Net block5,1943,8783,7193,8093,9104,0664,151
Capital work in progress978638670504268355320
Investments17,61617,35113,79411,90910,9749,7267,190
Inventories4,3543,6073,2543,2773,4863,0863,021
Sundry debtors3,3973,8602,6822,8882,7943,0353,560
Cash & bank balances5192783339661,428875523
Loans & advances2,8753,7744,2053,4671,5881,1911,088
Total current assets11,14411,52010,47410,6009,2968,1878,193
Total current liabilities3,8263,1522,8462,6852,6512,6692,613
Net working capital7,3188,3687,6287,9156,6455,5185,579
Total assets34,66732,41428,17424,87522,71820,19017,679
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash82.7416529.4817729526264.47
Net cash from operating activities2,8323,3013,7273,0352,7733,4602,018
Net cash from investing activities(1,344)(2,309)(2,883)(2,758)(2,464)(3,361)(1,127)
Net cash from financing activities(1,322)(1,074)(709)(425)(427)(65.80)(694)
Net change in cash166(81.78)135(148)(117)33.18197
Closing cash5192783339661,428875523
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+0.6%+14.1%+16.1%-2.1%+36.1%-10.7%-
EBITDA growth-27.5%+28.9%+41.6%-14.7%+21.0%+13.3%-
PBT growth-28.3%+21.8%+57.3%-13.0%+21.0%+8.2%+18.9%
Net income growth-28.5%+19.2%+58.0%-12.2%+19.8%+9.1%-
Revenue CAGR (3Y)+10.0%+9.1%+15.7%+6.0%+7.5%-0.3%+5.5%
EBITDA CAGR (3Y)+9.8%+15.9%+13.5%+5.4%+14.1%+13.1%+19.3%
Profitability & leverage
Net income margin+17.5%+25.9%+23.3%+16.7%+19.2%+21.8%+18.3%
Return on capital employed+13.9%+21.4%+20.1%+14.3%+18.2%+14.7%+17.8%
Return on net worth+10.6%+17.2%+15.5%+10.7%+13.9%+13.0%+14.0%
Debt / equity0.000.000.000.000.000.000.00
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover0.550.290.520.870.851.731.71
Efficiency & per share
Fixed asset turnover2.092.392.211.992.131.641.97
Inventory turnover5.045.825.354.454.683.704.30
Debtors turnover5.536.106.285.305.283.433.76
EPS (₹)43.5263.8650.5031.1436.6630.6128.75
Dividend per share (₹)13.0016.0013.008.505.005.004.00
Book value per share (₹)423.39397.46346.49305.25279.05247.10215.85
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Ciplamed

Maharashtra FDA Cancels Cipla Unit’s Drug Sale Licence Over Alleged Violations - Newspaper
Exchange Update • 24 days ago
Cipla and Qilu Pharmaceutical Form Licensing and Supply Deal for Keytruda Biosimilar in US
Contract Pharma • 1 month ago
China Biopharma Grants Cipla Exclusive License For TQB2102
Binance News • 1 month ago
Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate
Reuters • 1 month ago
Cipla licenses experimental HER2 cancer drug for India, South Africa and five other markets
CNBC-TV18 • 1 month ago
Bombay HC pulls up Maharashtra FDA over enforcement actions: What businesses need to know
Mint • 1 month ago
Maharashtra FDA cancels drug sale licences of Cipla Pharma & Life Sciences' Pune C&F unit
Moneycontrol • 2 months ago
Why has the Centre barred certain cold medicines for children under four?
Mint • 2 months ago
Global drugmakers invest billions to boost US presence
Reuters • 2 months ago
India's Zydus Life quarterly profit slumps as costs weigh
Reuters • 2 months ago
Premium access

Complete news archive for Ciplamed

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ciplamed

Ciplamed was founded in 2001.

Ciplamed is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Ciplamed has 25,952 employees.

The primary company behind Ciplamed, Cipla Limited, reported revenue of ₹39,894 Cr for FY 2026, up 5% year on year.

CiplaMed, operated by Cipla Limited, delivers digital resources like medical updates, conference highlights, and webcasts. Based in Mumbai, India, it focuses on healthcare education through platforms for eCME, expert talks, and patient materials, serving professionals to enhance knowledge and practice in areas such as cardiovascular and respiratory health.

Ciplamed offers eCME, Webcasts, and Quick Reads.

Yes, Ciplamed is publicly traded on NSE under the ticker symbol CIPLA.

Ciplamed operates through Cipla Limited.

The legal entities of Ciplamed currently have 12 directors, including Prathivadibhayankara Rajagopalan Ramesh, Mandar Purushottam Vaidya, Yusuf Khwaja Hamied and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available